FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer Pursuant to Rule 13a-16 under the Securities Exchange Act of 1934

For the month ended November, 2019

ICON plc

(Registrant's name)

333-08704

(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland (Address of principal executive offices)

Brendan Brennan, CFO
South County Business Park, Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
+353-1-291-2000

(Name, telephone number, email and/or facsimile number and address of Company contact person)

mulcate by check mark whether the registral	it tiles of will tile allitual rej	onts under cover rottii 20-1 of rottii 40-1.
	Form 20-F_X	Form 40-F
Indicate by check mark whether the registrar	nt is submitting the Form 6-	K in paper as permitted by Regulation S-T Rule 101(b)(1):
	Yes	NoX
Indicate by check mark whether the registrar	nt is submitting the Form 6- Yes	K in paper as permitted by Regulation S-T Rule 101(b)(7): NoX
Indicate by check mark whether the registrar	nt by furnishing the informa	tion contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule12g3-2(b) unde	er the Securities Exchange A	Act of 1934.
	Yes	NoX
If "Yes" is marked, indicate below the file nu	ımber assigned to the regist	rant in connection with Rule 12g3-2(b):82 N/A

EXHIBIT LIST

Exhibit Description

99.1 ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 19	934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.	

Date: November 27, 2019

ICON plc

/s/ Brendan Brennan

Brendan Brennan Chief Financial Officer

ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference

DUBLIN--(BUSINESS WIRE)--November 27, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. The presentation will be webcast live from 2pm EST.

A link to the live webcast will be available via the Investor section of our website under "Events".

About ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 99 locations in 40 countries and has approximately 14,600 employees as at September 30, 2019. Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON/ICLR-G

Contacts

Investor Relations +1888 381 7923 or Jonathan Curtain Vice President Corporate Finance and Investor Relations +353 1 291 2000